Mobile

A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastati...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006252-21

A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastatic ER+/PgR+/erbB2- Breast Cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy, in terms of PFS assessed by an independent radiology vendor, of bosutinib in combination with letrozole versus letrozole alone as first line treatment or as recurrence of adjuvant treatment for ER+/PgR+/erbB2- advanced or MBC in postmenopausal women.

Critère d'inclusion

  • Locally advanced or metastatic ER+/PgR+/erbB2-breast cancer in post-menopausal women

Liens